Diffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome

Diffuse alveolar haemorrhage (DAH) is a rare complication of antiphospholipid syndrome. With a mortality rate of 46%, early diagnosis and management remain an ongoing challenge. Case reports are limited, and management guidelines are not yet definitive. In this case report, we present a 43‐year‐old...

Descripción completa

Detalles Bibliográficos
Autores principales: Seth, Ishith, Bhagavata Srinivasan, Shyam Prakaash, Bulloch, Gabriella, Yi, Dong Seok, Frankel, Anthony, Hsu, Kelvin, Passam, Freda, Garsia, Roger, Corte, Tamera J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980908/
https://www.ncbi.nlm.nih.gov/pubmed/35414937
http://dx.doi.org/10.1002/rcr2.948
Descripción
Sumario:Diffuse alveolar haemorrhage (DAH) is a rare complication of antiphospholipid syndrome. With a mortality rate of 46%, early diagnosis and management remain an ongoing challenge. Case reports are limited, and management guidelines are not yet definitive. In this case report, we present a 43‐year‐old male with DAH who required high‐dose oral steroids, intravenous methylprednisolone cyclophosphamide and rituximab over 18 months to control life‐threatening episodes of pulmonary bleeding.

Ejemplares similares